AI

📊 Market Pulse 1. Basis Raises $100M at $1.15B Valuation for AI Accounting Agents Basis secured $100 million at a $1.15 billion valuation for AI accounting agents that operate autonomously. This isn’t another chatbot wrapper—it’s an autonomous system handling complex accounting workflows without human intervention. 🔗 TechCrunch 2. Runway Raises $315M at $5.3B Valuation — World Models Next AI video leader Runway secured $315 million Series E led by General Atlantic with Nvidia and Fidelity participating. Focus shifting to World Model development with applications in healthcare, climate, energy, and robotics. ...

🔄 The Shift: What’s Happening We assumed AI would automate physical labor first. Instead, it’s automating cognitive labor—precisely what made white-collar work “safe.” The numbers are stark: Prediction Source “Every white-collar task automated within 18 months” Microsoft AI Chief Mustafa Suleyman “AI will replace half of white-collar workers” Ford CEO Jim Farley Entry-level white-collar jobs could be halved Anthropic CEO Dario Amodei 92 million jobs displaced by 2030 Research forecast But here’s the counter-trend: ...

📊 Market Pulse 1. OpenAI Closing Historic Funding Round at $850B+ Valuation OpenAI is finalizing a massive funding round with a valuation exceeding $850 billion. Amazon, SoftBank, Nvidia, and Microsoft are participating. ChatGPT has begun testing ads for free users, signaling a shift toward revenue diversification beyond subscriptions. 🔗 TechCrunch 2. Anthropic Raises $30B Series G at $380B Valuation Anthropic announced a $30 billion Series G round with participation from Founders Fund, Coatue, Nvidia, and 30+ investors. Valuation reaches $380 billion as competition with OpenAI intensifies. ...

🧬 The New Reality of AI Biotech Generative AI and DeepMind’s innovations have completely transformed the biotech industry. Looking at what small and mid-sized AI biotech companies like AbCellera Biologics are facing, the survival rules of the AI era become crystal clear. ⚡ The Perfect Storm Facing AbCellera 1. Big Pharma’s Direct Investment Rush In 2026, major pharmaceutical companies completely changed their AI investment strategy. Partnership Details Eli Lilly + Chai Discovery Multi-target biological drug design platform GSK + Noetik $50M upfront for cancer prognosis prediction foundation model Pfizer + Boltz Exclusive model development for small molecule discovery Big Pharma is now skipping the “middleman” and partnering directly with AI platforms. The space for mid-sized biotechs like AbCellera is rapidly shrinking. ...